Synthego, a prominent provider of advanced genome editing solutions streamlining the journey from discovery to clinical application, has joined hands with bit.bio, a visionary entity specializing in programming human cells for groundbreaking medical solutions. The duo unveiled an impactful strategic partnership, united with the aim of constructing a cutting-edge platform focused on integrating synthetic circuitry within cells for therapeutic purposes.

bit.bio, at the forefront of this collaboration, is actively constructing a robust pipeline of cell therapies concentrated on addressing unmet clinical needs. This strategic alliance will leverage Synthego's profound expertise in gene editing, synergizing it with bit.bio's pioneering opti-oxTM precision cell programming technology. The overarching objective? To spearhead the exploration and development of advanced genetic engineering solutions, poised to redefine the realm of cell therapies.

A significant facet of this collaboration involves Synthego's rapid design, construction, testing, and delivery of an end-to-end optimized multiplexed genetic editing strategy. The integration of the multiplexed opti-ox engineering approach holds the potential to streamline the number of engineering steps required, thereby potentially shortening clinical cell engineering and development timelines by up to 10 months.

Paul Dabrowski, CEO at Synthego, articulated, "bit.bio is a trailblazer in the realm of synthetic biology with a laser focus on human cells. We are excited to deepen our collaboration with bit.bio, aiming to propel the development of synthetic biology-based cell therapies into a new era. By harmonizing our respective technologies, expertise, and resources, we envision novel avenues to tackle critical challenges in the field, thereby accelerating the R&D cycle of innovative cell therapies."

Mark Kotter, CEO at bit.bio, concurred, stating, "Synthego boasts unmatched expertise in industrialized cell engineering. Partnering with Synthego represents a significant enhancement to our genetic engineering capabilities. Anticipate efficiency enhancements across the entire bit.bio platform, enabling us and our collaborators to swiftly deliver transformative therapies to patients in dire need."

This collaboration between Synthego and bit.bio holds the promise of not just advancing research and development but potentially revolutionizing the landscape of medical solutions, heralding a new dawn in patient care.

 

Source: prnewswire.com

Report Abuse